Advantages and disadvantages of fludrocortisone or saline load in preventing post-spaceflight orthostatic hypotension.
The purpose of this study was to compare the effectiveness of saline load to fludrocortisone (florinef) as countermeasures for reduced plasma volume and orthostatic intolerance after spaceflight.  Eleven males (ages 30-50 yr) underwent a 3-day ambulatory baseline period followed by 7 days of 6 degrees head-down bedrest, during which cardiopulmonary and arterial baroreflex sensitivity and plasma volume (PV) were determined.  During pre-bedrest and 2.5 h after treatment on day 8, PV was also measured and subjects underwent a 15-min unsupported stand test.  Treatments consisted of 8 salt tablets (1 g NaCl per tablet) and 960 ml of water in 5 subjects and 0.6 mg (0.2 mg x 3) over 24 h in the other 6 subjects.  PV decreased by 12% on day 7 of bedrest.  This was restored on day 8 by florinef but not by saline load.  The effect of florinef on PV was paralleled by decreases in urine volume and the urinary sodium/potassium ratio.  Reduced PV was associated with greater vascular resistance for the same drop in central venous pressure, suggesting less vasoconstriction reserve after bedrest.  Carotid baroreflex control of heart rate was attenuated after 7 days of bedrest.  Both baroreflex functions were restored by florinef but not saline load.  Only 1 of 6 subjects showed syncopal symptoms in the florinef-treated group, whereas 4 of 5 subjects did so in the saline-load group.  Acute florinef treatment appears to have distinct advantages as a protective measure for post-bedrest orthostatic intolerance, not only through its salt retaining, volume-expanding mineralcorticoid effect, but possibly through its actions on baroreflex and sympathetic functions.
Vernikos
J
J
NASA Headquarters, Washington, DC 20546.
Convertino
V A
VA
D000284:Administration, Oral; D000328:Adult; D017704:Baroreflex / Q000502:physiology; D001510:Bed Rest / Q000009:adverse effects*; D005438:Fludrocortisone / Q000008:administration & dosage / Q000627:therapeutic use*; D018475:Head-Down Tilt / Q000009:adverse effects; D006439:Hemodynamics; D006801:Humans; D007024:Hypotension, Orthostatic / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010953:Plasma Volume; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D018544:Weightlessness Countermeasures; D018474:Weightlessness Simulation
D012965:Sodium Chloride; D012964:Sodium; D011188:Potassium; D005438:Fludrocortisone; D009638:Norepinephrine